Treats HIV1 infection. ANDA 204739, held by Macleods Pharms. Lopinavir; Ritonavir.
As of Nov 16, 2026, ANDA 204739 (Lopinavir And Ritonavir), held by Macleods Pharms, was first approved by FDA on Jul 25, 2024, with 0 approved supplements and 0 published complete response letters.
Lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV1 infection in adults and pediatric patients 14 days and older. Limitations of Use: Genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 25, 2024 | Original application | Approved | None posted |
| Lopinavir And Ritonavir100MG;25MG · tablet;oral | Lopinavir; Ritonavir | Rx |
| Lopinavir And Ritonavir200MG;50MG · tablet;oral | Lopinavir; Ritonavir | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters